Efficacy of NSAID vs. Steroid-NSAID Combo Post-Selective Laser Trabeculoplasty: Phase 4, Single-Center RCT

Launched by ST. JOSEPH'S HEALTHCARE HAMILTON · Jul 5, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring the best way to reduce inflammation and control eye pressure after a specific eye surgery called Selective Laser Trabeculoplasty (SLT) in patients with open-angle glaucoma. Researchers want to see how effective a single medication called ketorolac is when used alone compared to using it in combination with another medication called fluorometholone, which is a type of steroid. There is also a group of participants who will not receive any medication after the surgery, which will help in determining the best postoperative care.

To be eligible for this trial, participants must be adults aged 18 and older who have been diagnosed with open-angle glaucoma and have high eye pressure. They should have good enough vision in at least one eye. Potential participants will need to attend several follow-up visits over the course of a year to monitor their recovery. It’s important to note that individuals with certain other eye issues, those who are pregnant or breastfeeding, or those allergic to the study medications will not be able to participate. This study aims to provide clearer guidance for doctors on how to manage care after eye surgery for better patient outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults aged 18 years and older.
• • Diagnosed with open-angle glaucoma.
• • Intraocular pressure (IOP) greater than 16 mmHg on at least two consecutive occasions separated by one month.
• • Visual acuity of 20/200 or better in at least one eye.
• • Provided informed consent.
• Exclusion Criteria:
• • Patients with any other ocular disorders or surgeries within the last six months.
• • Allergy or intolerance to ketorolac or fluorometholone.
• • Previous use of systemic ketorolac or fluorometholone in the past month.
• • Pregnancy or breastfeeding.
• • Patients who are unable to speak/understand English.
• • Any condition that in the investigator's opinion would make participation not in the best interest of the patient or could prevent, limit, or confound the protocol-specified assessments.